KR20200036873A - 캡슐화된 폴리뉴클레오티드 및 사용 방법 - Google Patents

캡슐화된 폴리뉴클레오티드 및 사용 방법 Download PDF

Info

Publication number
KR20200036873A
KR20200036873A KR1020207004226A KR20207004226A KR20200036873A KR 20200036873 A KR20200036873 A KR 20200036873A KR 1020207004226 A KR1020207004226 A KR 1020207004226A KR 20207004226 A KR20207004226 A KR 20207004226A KR 20200036873 A KR20200036873 A KR 20200036873A
Authority
KR
South Korea
Prior art keywords
mir
recombinant dna
dna molecule
virus
sequence
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
KR1020207004226A
Other languages
English (en)
Korean (ko)
Inventor
미첼 에이치. 피너
에드워드 케네디
로레나 레르너
Original Assignee
온코루스, 인크.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 온코루스, 인크. filed Critical 온코루스, 인크.
Publication of KR20200036873A publication Critical patent/KR20200036873A/ko
Ceased legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
    • C12N15/88—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation using microencapsulation, e.g. using amphiphile liposome vesicle
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/111—General methods applicable to biologically active non-coding nucleic acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/32011—Picornaviridae
    • C12N2770/32021—Viruses as such, e.g. new isolates, mutants or their genomic sequences
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/32011—Picornaviridae
    • C12N2770/32023—Virus like particles [VLP]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/32011—Picornaviridae
    • C12N2770/32032—Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/32011—Picornaviridae
    • C12N2770/32041—Use of virus, viral particle or viral elements as a vector
    • C12N2770/32043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector

Landscapes

  • Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Plant Pathology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Virology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
KR1020207004226A 2017-07-14 2018-07-13 캡슐화된 폴리뉴클레오티드 및 사용 방법 Ceased KR20200036873A (ko)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201762532886P 2017-07-14 2017-07-14
US62/532,886 2017-07-14
US201862648651P 2018-03-27 2018-03-27
US62/648,651 2018-03-27
PCT/US2018/042136 WO2019014623A1 (en) 2017-07-14 2018-07-13 Encapsulated polynucleotides and methods of use

Publications (1)

Publication Number Publication Date
KR20200036873A true KR20200036873A (ko) 2020-04-07

Family

ID=65002120

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020207004226A Ceased KR20200036873A (ko) 2017-07-14 2018-07-13 캡슐화된 폴리뉴클레오티드 및 사용 방법

Country Status (13)

Country Link
US (1) US20200224220A1 (cg-RX-API-DMAC7.html)
EP (1) EP3652325A4 (cg-RX-API-DMAC7.html)
JP (2) JP2020530778A (cg-RX-API-DMAC7.html)
KR (1) KR20200036873A (cg-RX-API-DMAC7.html)
CN (1) CN111212914A (cg-RX-API-DMAC7.html)
AU (1) AU2018301701A1 (cg-RX-API-DMAC7.html)
BR (1) BR112020000839A2 (cg-RX-API-DMAC7.html)
CA (1) CA3069821A1 (cg-RX-API-DMAC7.html)
IL (1) IL271969A (cg-RX-API-DMAC7.html)
MX (1) MX2020000495A (cg-RX-API-DMAC7.html)
RU (1) RU2020106730A (cg-RX-API-DMAC7.html)
SG (1) SG11202000312UA (cg-RX-API-DMAC7.html)
WO (1) WO2019014623A1 (cg-RX-API-DMAC7.html)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2026071633A1 (ko) * 2024-09-24 2026-04-02 고려대학교 산학협력단 폐암 치료를 위한 페메트렉시드-기능화 종양 미세환경 표적 흡입용 약물전달시스템

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2020000993A (es) 2017-07-26 2020-07-22 Oncorus Inc Vectores virales oncolíticos y usos de estos.
MX2020001593A (es) 2017-08-09 2020-07-13 Bioverativ Therapeutics Inc Moleculas de acido nucleico y usos de las mismas.
SG11202006457YA (en) 2018-01-05 2020-08-28 Ottawa Hospital Res Inst Modified orthopoxvirus vectors
US20200405791A1 (en) * 2018-03-12 2020-12-31 Mayo Foundation For Medical Education And Research Using infectious nucleic acid to treat cancer
JP7602454B2 (ja) 2018-08-09 2024-12-18 バイオベラティブ セラピューティクス インコーポレイテッド 核酸分子及び非ウイルス遺伝子治療のためのそれらの使用
DK3864163T3 (da) 2018-10-09 2024-05-06 Univ British Columbia Sammensætninger og systemer omfattende transfektionskompetente vesikler fri for organiske opløsningsmidler og rengøringsmidler og fremgangsmåder forbundet dermed
CA3117924A1 (en) * 2018-11-13 2020-05-22 Oncorus, Inc. Encapsulated polynucleotides and methods of use
CA3124524A1 (en) * 2019-01-04 2020-07-09 Oncorus, Inc. Encapsulated rna polynucleotides and methods of use
US12209250B2 (en) * 2019-03-14 2025-01-28 Massachusetts Institute Of Technology Engineered Herpes Simplex Virus-1 (HSV-1) vectors and uses thereof
JP2022543610A (ja) * 2019-08-05 2022-10-13 ヴァイロジン バイオテック カナダ リミテッド 遺伝子改変エンテロウイルスベクター
CN114765990A (zh) * 2019-10-10 2022-07-19 昂克诺斯公司 双重病毒和双重溶瘤病毒以及治疗方法
EP4157456A4 (en) * 2020-05-29 2024-06-26 Oncorus, Inc. ENCAPSULATED RNA REPLIKONS AND METHODS OF USE
EP4164596A1 (en) * 2020-06-11 2023-04-19 eTheRNA Immunotherapies NV Lipid nanoparticles
US20230242994A1 (en) * 2020-07-10 2023-08-03 Shanghai Miran Biotech Co., Ltd. Fluorescent cross-linked rnase h mutant conjugate, mirna combination and application thereof
CA3204244A1 (en) * 2021-01-06 2022-07-14 Lorena Lerner Encapsulated rna polynucleotides and methods of use
CN113368261A (zh) * 2021-06-17 2021-09-10 苏州大学 一种非病毒载体及其制备方法与应用
WO2023069948A1 (en) 2021-10-18 2023-04-27 Flagship Pioneering Innovations Vii, Llc Dna compositions and related methods
US20250304999A1 (en) * 2022-05-20 2025-10-02 Virogin Biotech Canada Ltd Genetically modified enterovirus vectors with enhanced genomic stability
JP7229412B1 (ja) 2022-06-14 2023-02-27 キユーピー株式会社 脂質ナノ粒子及びその製造方法
CN118634240A (zh) * 2022-06-27 2024-09-13 浙江大学 抗口腔肿瘤药物活性成分及其用途

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2004274860A1 (en) * 2003-05-28 2005-03-31 Wisconsin Alumni Research Foundation Recombinant influenza vectors with a polII promoter and ribozymes
DK1668025T3 (da) * 2003-09-26 2014-08-25 Novartis Ag Seneca Valley-virusbaserede præparater og fremgangsmåder til behandling af sygdom
US7473418B2 (en) * 2004-03-25 2009-01-06 Cell Genesys, Inc. Pan cancer oncolytic vectors and methods of use thereof
GB0810912D0 (en) * 2008-06-13 2008-07-23 Inst Animal Health Ltd Vector
DK2346995T3 (en) * 2008-09-26 2019-02-11 Tocagen Inc GENETERIVE VECTORS AND CYTOSINDEAMINASES
CA2782366A1 (en) * 2009-12-16 2011-07-14 Opko Curna, Llc Treatment of membrane bound transcription factor peptidase, site 1 (mbtps1) related diseases by inhibition of natural antisense transcript to mbtps1
WO2013083753A2 (en) * 2011-12-07 2013-06-13 Institut Pasteur Identification of a swine parecho-like virus and applications
WO2013156989A1 (en) * 2012-04-18 2013-10-24 Ramot At Tel-Aviv University Ltd. Lipidated glycosaminoglycan particles for the delivery of nucleic acids
WO2014171526A1 (ja) * 2013-04-17 2014-10-23 国立大学法人九州大学 遺伝子改変コクサッキーウイルス
US10513711B2 (en) * 2014-08-13 2019-12-24 Dupont Us Holding, Llc Genetic targeting in non-conventional yeast using an RNA-guided endonuclease
HK1246183A1 (zh) * 2015-06-10 2018-09-07 Hookipa Biotech Gmbh Hpv疫苗
WO2017096201A1 (en) * 2015-12-02 2017-06-08 Memorial Sloan-Kettering Cancer Center Seneca valley virus (svv) cellular receptor targeted oncotherapy

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2026071633A1 (ko) * 2024-09-24 2026-04-02 고려대학교 산학협력단 폐암 치료를 위한 페메트렉시드-기능화 종양 미세환경 표적 흡입용 약물전달시스템

Also Published As

Publication number Publication date
BR112020000839A2 (pt) 2020-07-21
JP2020530778A (ja) 2020-10-29
EP3652325A4 (en) 2021-09-15
SG11202000312UA (en) 2020-02-27
IL271969A (en) 2020-02-27
CN111212914A (zh) 2020-05-29
RU2020106730A (ru) 2021-08-16
EP3652325A1 (en) 2020-05-20
CA3069821A1 (en) 2019-01-17
US20200224220A1 (en) 2020-07-16
AU2018301701A1 (en) 2020-02-27
JP2023165916A (ja) 2023-11-17
WO2019014623A1 (en) 2019-01-17
MX2020000495A (es) 2020-08-20

Similar Documents

Publication Publication Date Title
JP2023165916A (ja) カプセル封入ポリヌクレオチド及び使用方法
CN113348246A (zh) 包封多核苷酸及使用方法
JP7428664B2 (ja) 合成肝臓指向性アデノ随伴ウイルスカプシドおよびその使用
ES2256265T3 (es) Vectores de parvovirus duplicados.
CN113453699A (zh) 包封的rna多核苷酸及使用方法
BR112020013319A2 (pt) vetores de dna de extremidade fechada obteníveis a partir de síntese livre de células e processo para obter vetores de cedna
JP7644014B2 (ja) 閉端DNA(ceDNA)の産生におけるREPタンパク質活性の調節
JP7583732B2 (ja) フェニルアラニンヒドロキシラーゼ(pah)治療薬を発現するための非ウイルス性dnaベクターおよびその使用
CN113316640A (zh) 包含对称的被修饰的反向末端重复序列的被修饰的封闭端dna(cedna)
CN113874513A (zh) 非病毒dna载体及其用于表达fviii治疗剂的用途
KR20220078650A (ko) 이중 바이러스 및 이중 종양용해 바이러스 및 치료 방법
JP2022523806A (ja) 閉端dna(cedna)および免疫調節化合物
JP2023542131A (ja) フェニルアラニンヒドロキシラーゼ(pah)を発現させるための閉端dnaベクター及びその使用
HK40029850A (en) Encapsulated polynucleotides and methods of use
CN119233824A (zh) 编码小核糖核酸病毒的rna多核苷酸的产生

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20200213

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
A201 Request for examination
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20210713

Comment text: Request for Examination of Application

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20230921

Patent event code: PE09021S01D

E601 Decision to refuse application
PE0601 Decision on rejection of patent

Patent event date: 20240415

Comment text: Decision to Refuse Application

Patent event code: PE06012S01D

Patent event date: 20230921

Comment text: Notification of reason for refusal

Patent event code: PE06011S01I